Long-Term Follow Up Study for AMD3100 Patients

Completed · Has a placebo group

Conditions studied: Myeloma

In brief

Objectives: The objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor \[AMD3100\]) in protocol AMD3100-3102. Patients that received at least 1 dose of study treatment (placebo or plerixafor) in the multicenter, randomized, double-blind, placebo-controlled AMD3100-3102 study, which was designed to evaluate plerixafor plus granulocyte colony stimulating factor (G-CSF) versus placebo plus G-CSF to mobilize hematopoietic stem cells for autologous transplantation of Multiple Myeloma (MM) patients are eligible.

Key facts

Study ID

NCT00476294

Run by

M.D. Anderson Cancer Center

People needed

7

Starts

2006-10-01

Expected to finish

2012-07-01

Last updated by the study team

2012-07-11

Who can join

Age: 18 and older, up to 78. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1) All patients who received the study drug (placebo or plerixafor) on protocol AMD3100-3102 (2004-0982)
• Exclusion Criteria: None

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.